N/A N=68 A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans
Intestinal FDG Uptake
Primary: SUVmax of FDG in Each Colonic Segment — 4.6; 4.3 SUV
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=19 FDG-PET/CT in the Evaluation of Patients With Suspected Cholecystitis
Cholecystitis
Primary: Sensitivity and Specificity of FDG PET/CT and Tc99mHIDA in the Evaluation of Subjects Suspected of Cholecystitis — 9; 0; 1; 1 Participants
N/A N=44 FDG Uptake in Vaginal Tampons is Due to Urine
Cancer
Primary: Number of FDG Positive Tampoons — 2; 10 FDG positive tampons
N/A N=133 Patterns and Prevalence of FDG Extravasation in PET/CT Scans
Intravenous Infiltration
Primary: Number of Participants With Intraveneous Infiltration of FDG During Routine PET/CT Imaging by Visually Assessment of Interpreting Physicians — 17; 32 Participants
Phase 2 N=63 Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
PDAC - Pancreatic Ductal Adenocarcinoma · FAP
Primary: Sensitivity of [68Ga]FAPI-46 PET Imaging to Detect PDAC, Using Histopathology as Truth Standard — 0.741 proportion of participants
N/A N=4 Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract
High Risk Polyposis Syndrome · Distal Colonic Lesions · Colorectal Polyps
Primary: Number of Neoplastic Lesions Detected — 3 Lesions
Phase 3 N=12 PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis
Diabetes · Gastroparesis With Diabetes Mellitus
Primary: Uptake of 11C-ER 176 in the Stomach Muscle — 5.5; 8.4; 4.6; 7.8 SUVmax
N/A N=174 TOF-18F-FDG-PET/CT in Patients With Suspected Pancreatic Cancer
Pancreatic Cancer · Pancreatitis · IPMN
Primary: SUVmax (Maximal Standard Uptake Value) Measurement 30 and 90 Min p.i. (Post Injection) — 0.77; 0.78; 0.81; 0.8 SUVmax — p=0.78
Phase 2 N=106 Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism
Congenital Hyperinsulinism · Hyperinsulinism · Persistent Hyperinsulinemic Hypoglycemia of Infancy
Primary: The Accuracy of FDOPA PET to Identify Focal Forms of Hyperinsulinism — 40; 6; 3; 46 Participants
Phase 2 N=36 [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
Uterine Cervical Neoplasms · Endometrial Neoplasms · Anus Neoplasms
Primary: Percent Difference From Baseline IMRT Plan (%) — -4.7; -9.3; -14.2; -13.4 Percent difference (%)
Phase 1 N=9 Detection of Graft Versus Host Disease With [18F]F-AraG
Graft Versus Host Disease
Primary: Distribution of Acute GVHD Grades (MAGIC Criteria) at Time of PET/CT Scan — 0; 2; 0; 0 Participants
N/A N=21 FDG-PET Imaging in Young Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Kinetic Influx Constant (Ki) — 0.009; 0.013 mL/min/mL
N/A N=25 Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Cystic Fibrosis
Primary: Orocaecal Transit Time — 330; 210 minutes — p=0.04
N/A N=4 Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas
Parathyroid Disease
Primary: Detection Rate of Parathyroid Adenomas of Anti-3-[18F]FACBC Modality — 80 percentage of adenomas detected
Phase 2 N=384 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Cell Carcinoma · Cervical Small Cell Carcinoma
Primary: The Diagnostic Sensitivity of PET/CT for Detection of Lymph Node Metastasis in Abdomen — 50; 65 percentage of participants
Phase 2 N=46 18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules
Lung Carcinoma · Solitary Pulmonary Nodule · Cigarette Smoking Behavior
Primary: Ability of 18F-FSPG PET/CT to Discriminate Benign From Malignant Nodules — 0.706; 0.778; 0.731; 0.817 proportion, range 0 to 1, higher better
Phase 2 N=9 Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours.
Neuroendocrine Tumors
Primary: To Determine the Biodistribution of [18F] Following Single I.V Administration of [18F]-FET-βAG-TOCA Injection in Patients With a Histological Diagnosis of NET. — 0.002…
Phase 2 N=114 Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Cancer
Primary: Cohort 1 - NaF PET/CT vs 99mTc-MDP Bone Scintigraphy — 10; 0; 0 Participants
Phase 1 N=15 [F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors
Cancer · Brain Tumors
Primary: Area Under the Receiver Operating Curve (ROC AUC) Values for PET Imaging Techniques — 0.98; 0.91; 0.89; 0.82 Probability
Phase 2 N=7 18F-FSPG PET/CT for Cancer Patients on Therapy
B-Cell Neoplasm · Estrogen Receptor Negative · HER2/Neu Negative
Primary: Change From Baseline in Standard Uptake Value Maximum (SUVmax) Post-treatment — -1.69; -0.64 g/mL
N/A N=21 Molecular and Whole-body MR Imaging in Lymphomas
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value
Phase 4 N=15 d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis
Cardiac Sarcoidosis
Primary: 68Ga-DOTATATE Uptake With Cardia Sarcoidosis (CS)
Phase 2 N=97 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer
Neuroendocrine Carcinoma
Primary: Number of Patients That Experienced a Change in Care Plans After 68GA-DOTATATE PET Scan — 19; 9; 50 participants
Early Phase 1 N=27 Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
Breast Cancer · Non-Small-Cell Lung Cancer · Glioblastoma
Primary: Tracer Dosimetry by Organ — 0.3603; 0.0988; 0.8615; 0.5290 mSv/MBq
Phase 2 N=128 Phase II Safety and Efficacy Study of 18FDOPA PET-CT in Children With Hyperinsulinemic Hypoglycemia
Congenital Hyperinsulinism (CHI) · Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Primary: Accuracy of 18F-DOPA PET/CT Scans to Detect Focal Lesions in Children With Congenital Hyperinsulinism — 34; 10; 4; 52 cases
N/A N=48 Evaluation of the Gastrointestinal Manifestation of Fabry's Disease
Fabry's Disease
Primary: Gastric Emptying Transit Time Measured Via SmartPill Study — 2.9; 2.8 Hours
N/A N=5 FLT PET/CT for Staging, Target Definition and Assessment of Response to Therapy in Patients With Esophageal Cancer
Esophageal Cancer
Primary: Feasibility: Determined by the Number of Participants Who Had All Three Sets of Completed Serial PET Scans That Were Imported for Analysis — 5 participants
N/A N=10 MSG Use With 18F-DCFPyL PET/CT Imaging
Prostate Cancer · Prostate Cancer Metastatic · Prostatic Neoplasm
Primary: Salivary Gland Maximal Standardized Uptake Values Corrected for Lean Body Mass (SULmax) for 18F-DCFPyL — 9.9; 15.1 SULmax — p=<0.001
N/A N=152 18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Primary: Overall Survival — 56; 29 months
N/A N=130 Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer
Muscle Invasive Bladder Cancer
Primary: Accuracy of the PET CT for Lymph Node Staging in Terms of Sensitivy Rate — 21 Participants